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The dopamine D2 antagonists used as antipsychotic treatments 
are invaluable for many people with schizophrenia but can be 
limited by a range of adverse effects. These depend on the phar-
macological profile of the antipsychotic drug used, as well as on 
genetic and other individual features of the patient, and include 
inter alia extrapyramidal symptoms (EPS), elevated prolactin, 
sedation, postural hypotension, weight gain and QT interval pro-
longation. The underlying receptor mechanisms relate to antago-
nism at, respectively but not exclusively, striatal and pituitary D2 
receptors, histamine H1, alpha1 adrenergic, H1 and 5-HT2C 
receptors and hERG ion channels. In general, these side effects 
are dose-dependent, consideration of which has prompted the 
introduction of guidelines aimed at avoiding excessively high 
doses of antipsychotic drug. Furthermore, it has been established 
that for most dopamine D2 antagonists a D2 receptor blockade of 
approximately 60%–70% is adequate for an antipsychotic action 
and that drug doses above those required to achieve this threshold 
are likely to increase side effects without a concomitant increase 
in efficacy (Farde et al., 1992; Kapur et al., 2000).
This argument is also true for combinations of D2 antagonist 
drugs; the UK consensus guidelines indicate that the ‘high dose’ 
threshold is reached when the sum of the percentage of the maxi-
mum recommended dose for each antipsychotic drug exceeds 
100% (Royal College of Psychiatrists, 2014). The rationale is 
clear: Combining two D2 antagonists at half maximum dose 
should approximate to the effects of one drug at maximum dose, 
although it is limited by inconsistencies in determining maxi-
mum doses, with newer drugs generally having more constrained 
dose ranges.
The availability of aripiprazole and cariprazine, as well as 
brexpiprazole in many countries outside the UK, has provided 
psychiatry with useful alternatives to the various dopamine D2 
receptor antagonists that have been the mainstay in the treatment 
of psychosis for over 60 years. These three drugs are dopamine 
D2 receptor partial agonists which also have some further phar-
macological properties; for aripiprazole this includes 5-HT1A 
partial agonism and 5-HT2A antagonism, whilst cariprazine has 
a partial agonist affinity for D3 higher than that for D2 and antag-
onist action at 5-HT2B (Frankel and Schwartz, 2017). Both drugs 
have minimal or, at most, weak effects at histamine H1, mus-
carinic or adrenergic receptors.
These pharmacological profiles have resulted in the availabil-
ity of antipsychotic pharmacotherapy that is relatively free of 
some limiting side effects including hyperprolactinaemia and QT 
prolongation, as well as reductions in sedation (particularly for 
cariprazine) and in the requirement for antiparkinsonian medica-
tion (particularly for aripiprazole) (Huhn et al., 2019).
There is little evidence to support switching between antipsy-
chotic drugs to improve efficacy (Barnes et al., 2020), although 
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Guidelines for the treatment of schizophrenia limit the use of antipsychotic agents to clinically-established maximum doses. This acknowledges both 
the absence of additional efficacy of dopamine D2 receptor antagonists above a receptor occupancy threshold, and the increases in side effects 
that can occur at higher doses. These limits restrict the dosing of combinations of antipsychotics as they do single agents; drugs sharing the major 
antipsychotic mechanism of D2 receptor antagonism will act additively in blocking these receptors.
Several newer antipsychotic drugs, including aripiprazole and cariprazine, act as partial agonists at the D2 receptor site and avoid action at several 
other receptors, effects at which are responsible for some non-dopaminergic adverse effects. This pharmacology imparts different characteristics to 
the drugs resulting often in a more favourable side effect profile. Their partial agonism, along with high affinities for the D2 receptor, also means 
that these drugs given adjunctively may in part replace, rather than enhance, the D2 antagonism of other antipsychotic agents. This can result in an 
improvement in certain side effects without loss of antipsychotic efficacy.
This article makes the case for distinguishing the D2 partial agonists from antagonists in defining maximum doses of combined treatments, which 
would increase the options available to the prescriber, emphasising that pharmacological mechanisms need to be understood in identifying optimal 
treatments for psychotic illness.
Keywords
Antipsychotic agents, adjunctive treatment, dopamine D2 receptor, antagonists, partial agonists
Biomolecular Sciences Research Centre, Sheffield Hallam University, 
Sheffield, United Kingdom
Corresponding author:
Gavin P Reynolds, Biomolecular Sciences Research Centre, Sheffield 
Hallam University, Howard Street, Sheffield S1 1WB, United Kingdom. 
Email: gavin.reynolds@shu.ac.uk




recent studies have indicated some differences in which amisul-
pride, olanzapine and risperidone, as well as clozapine, show 
small advantages in overall efficacy (Smith et al., 2019). Stronger 
justification for switching is found in response to side effects 
which may differ substantially between drugs. Here the D2 par-
tial agonists may demonstrate particular benefits. With these 
drugs, however, switching from a D2 antagonist may not be 
immediately necessary; the benefits of aripiprazole (and likely 
cariprazine too) in reducing drug-induced hyperprolactinaemia, 
for example, can be seen when the drug is added to current treat-
ment (Zheng et al., 2019). Similarly, adjunctive aripiprazole can 
ameliorate weight gain and other metabolic problems associated 
with olanzapine or clozapine treatment (Cooper et al., 2016; 
Mizuno et al., 2014). Usually there is no deterioration of psy-
chotic symptoms associated with adding a dopamine partial ago-
nist; further symptomatic improvement may even be seen (e.g. 
Zheng et al., 2019). Such adjunctive prescribing would be off-
label but has a strong evidence base. It could, however, also serve 
as an initial step towards D2 partial agonist monotherapy, prior to 
a gradual withdrawal of the D2 antagonist drug.
Combination of two antipsychotic agents in this way may exceed 
the high dose threshold. Such cumulative doses are perceived as 
high risk and understandably may require explicit justification for 
their prescription. British Association for Psychopharmacology 
guidelines indicate that antipsychotic augmentation to address inad-
equate symptom response should only be considered after other 
treatment options have been exhausted, including ‘several, adequate, 
sequential trials of antipsychotic monotherapy’ (Barnes et al., 2020). 
This both reflects and guides current UK practice where switching is 
generally preferred to augmentation with another antipsychotic 
drug, despite the acknowledged paucity of supportive evidence. This 
often means that drug combinations are avoided with alternative, but 
perhaps sub-optimal, strategies being employed.
As mentioned above, the pharmacological basis for this high 
dose risk is clear; additional blockade of D2 receptors above 
what is necessary for an antipsychotic response will increase the 
liability for dopaminergic side effects such as EPS and prolactin 
secretion without increasing efficacy. Furthermore, and depend-
ing on the particular drugs being combined, other receptor-medi-
ated side effects are likely to increase, some of which, such as 
metabolic effects and QT prolongation, may contribute to 
increased mortality. However, this pharmacological argument 
does not consistently hold up for the combination of partial ago-
nists with antagonists. In terms of the main antipsychotic mecha-
nism, drug action at the dopamine D2 receptor, the dopamine D2 
partial agonists should be differentiated from D2 antagonists. As 
can be seen in their effects in avoiding, and reversing, D2 antag-
onist-induced hyperprolactinaemia, adjunctive partial agonists 
can ameliorate, rather than enhance, unwanted dopaminergic 
effects of D2 antagonists. Aripiprazole and cariprazine have high 
(sub-nanomolar) affinities at the D2 receptor greater than most 
D2 antagonists (Frankel and Schwartz, 2017). Thus they will 
preferentially bind to the receptor site, resulting in replacing 
antagonism with partial agonism, thereby providing a level of 
receptor stimulation which depends on the drug’s intrinsic activ-
ity; for aripiprazole this is around 25% of that of dopamine (Cosi 
et al., 2006).
This provides a strong argument for differentiating the D2 
partial agonists from the D2 antagonist drugs and considering 
them a separate class when it comes to combining drugs for the 
optimal treatment of people with psychotic illness. Of course, 
polypharmacy is to be avoided where possible and drugs need to 
be given at the lowest dose consistent with optimising efficacy 
and minimising side effects. However, it is clearly wrong to 
restrict adjunctive use of D2 partial agonists, where they may 
have clinical value, on the basis of the inappropriate application 
of a ‘maximum cumulative dose’ concept.
As a postscript, I suggest that the issue highlighted here is 
related to the common view of ‘antipsychotic agents’ as a single 
drug class or, at best, one divided into first- and second-genera-
tion antipsychotics. The application of neuroscience-based 
nomenclature, in which drugs are differentiated on the basis of 
their pharmacological mechanisms (Nutt and Blier, 2016), takes 
one step towards avoiding this oversimplification and its conse-
quences for psychiatric pharmacotherapy.
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Clinical guidelines for the treatment of schizophrenia consist-
ently recommend the use of a single antipsychotic in a standard 
dose (Barnes et al., 2020; National Institute for Health and Care 
Excellence, 2014; Galletly et al., 2016); this strategy is under-
pinned by both a large body of evidence supporting the efficacy 
of individual antipsychotic medications and by tolerability data 
that have been systematically, although not always comprehen-
sively, garnered (Pope et al., 2010). These guidelines further rec-
ommend switching to an alternative antipsychotic medication if 
the first antipsychotic is not tolerated or the illness fails to 
respond, although the paucity of supportive evidence for such 
switching is acknowledged. Should there be a persistent lack of 
adequate therapeutic response, timely progression to clozapine 
treatment should be the next step, in advance of the use of high-
dosage antipsychotic medication or combined antipsychotic 
medication strategies (which commonly result in a high-dose 
regimen), for which the evidence regarding treatment outcomes 
and safety is considerably slimmer.
Reynolds argues that, when added to another antipsychotic 
medication, D2 partial agonists reduce metabolic and prolactin-
related side effects and potentially improve symptom control: 
therefore the use of such combinations should be considered ear-
lier when seeking to optimise treatment for schizophrenia. But 
any additional beneficial effect on symptoms and side-effects 
with a D2 partial agonist/D2 antagonist combination is likely to be 
very modest and the combination may be associated with new 
side effects, so a favourable balance of risks and benefits cannot 
be assumed. Most of the clinical literature relating to D2 partial 
agonists focuses on aripiprazole as this antipsychotic medication 
was first in class. Therefore, aripiprazole is used to expand on 
these points below.
Efficacy and tolerability of 
aripiprazole as monotherapy
While aripiprazole has evident antipsychotic efficacy, it may be 
slightly less effective overall for treating the symptoms of schizo-
phrenia than the more commonly used D2 antagonists (Leucht 
et al., 2013; Tiihonen et al., 2019), suggesting that D2 partial ago-
nism may provide less than optimal control of symptoms in some 
cases. There are a further group of patients whose illness has 
shown an insufficient response to non-clozapine antipsychotic 
medication that is not related to factors such as poor adherence or 
comorbid substance use. Such treatment-resistant schizophrenia 
may have a distinct pathophysiology involving a range of neuro-
biological pathways (Potkin et al., 2020). Therefore, pharmaco-
logical strategies that are limited to modulating D2 receptor 
activity, either as monotherapy or in combination, may have 
minimal if any effect on symptoms and pursuing such strategies 
could result in an avoidable delay in initiating clozapine treat-
ment, potentially worsening outcomes (Shah et al., 2018; 
Yoshimura et al., 2017).
When used alone, aripiprazole is undoubtedly relatively 
well tolerated with respect to metabolic and prolactin-related 
side effects (Leucht et al., 2013) but it is not free of side effects, 
with treatment-emergent akathisia, insomnia, headache and 
nausea reported for more than 1 patient in 10 in clinicial trials 
(Aripiprazole SmPC). With respect to QTc prolongation, epide-
miological studies have linked aripiprazole to weak/moderate 
tosardogenicity (Polcwiartek et al., 2015). Further, recent evi-
dence points to an association between D2 partial agonists and 
the development of impulse control disorders (Corbeil et al., 
2021; Grall-Bronnec et al., 2016). Therefore, as is the case for 
all antipsychotic medications, the decision to prescribe ari-
piprazole should take into consideration the potential harms 
associated with this medication and ongoing clinical review is 
essential.
Efficacy and tolerability of 
aripiprazole in combination with 
another antipsychotic medication
While to our knowledge there are no randomised controlled trials 
of aripiprazole augmentation of non-clozapine antipsychotic 
medication, the real life effectiveness of such combinations has 
been reported by Tiihonen et al. (2019). In a Swedish, popula-
tion-based cohort of 62,500 patients with an established diagno-
sis of schizophrenia, those patients who were prescribed 
clozapine, olanzapine or a long-acting injectable antipsychotic 
preparation as monotherapy were less likely to be readmitted to 
hospital than those prescribed aripiprazole combined with a non-
clozapine antipsychotic. Further, olanzapine monotherapy fared 
slightly better than olanzapine combined with aripiprazole. Thus, 
these findings failed to suggest any systematic efficacy advan-
tage for the addition of aripiprazole to a non-clozapine antipsy-
chotic medication.
With respect to aripiprazole augmentation of clozapine, a 
meta-analysis of mostly very small randomised controlled trials 
found no advantage with respect to psychotic symptoms in clo-
zapine responders who received aripiprazole as a strategy to 
manage weight gain but a potential modest advantage with 
respect to improvement in negative symptoms where the illness 
had not responded to clozapine (Srisurapanont et al., 2015). In 
the naturalistic study by Tiihonen et al. (2019) described above, 
the combination of clozapine and aripiprazole was most effective 
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in preventing readmission but, compared with clozapine mono-
therapy, the effect size was small. When considered together, 
these studies do not exclude a modest advantage for an individual 
treatment trial of the combination over clozapine monotherapy 
for some particular patients, but the evidence so far falls short of 
supporting routine use.
Aripiprazole binds strongly to D2 receptors but the degree of 
dopamine blockade it produces is limited as it is a partial agonist 
rather than an antagonist. Through this mechanism, adjunctive 
aripiprazole has been shown to reverse the hyperprolactinaemia 
that is associated with some potent D2 antagonists, such as risp-
eridone (Yasui-Furukori et al., 2010). However hyperprolactinae-
mia that is asymptomatic does not always require treatment and 
where it is symptomatic or the patient is otherwise at greater risk 
of sequelae, the most logical strategy would be to switch to an 
antipsychotic medication with a low propensity for elevating 
plasma prolactin.
With respect to the amelioration of weight gain associated 
with antipsychotic treatment, published meta-analyses (Choi, 
2015; Srisurapanont et al., 2015) have concluded that the addi-
tion of aripiprazole to clozapine or olanzapine results in a mean 
weight change of around -2 kg compared with clozapine or olan-
zapine monotherapy. This mean change is modest and while it 
does not exclude a larger effect in some patients, it suggests that 
for the majority the effect on body weight is unlikely to be clini-
cally relevant. The use of adjunctive aripiprazole to reduce 
weight gain in patients receiving antipsychotic medications other 
than clozapine or olanzapine has not been systematically tested. 
While the BAP guidelines for the management of weight gain, 
metabolic disturbances and cardiovascular risk associated with 
psychosis and antipsychotic treatment (Cooper et al, 2016) iden-
tified augmentation of clozapine or olanzapine with aripiprazole 
as a possible intervention for weight gain, it added the caveat that 
the possible disadvantages of such polypharmacy should be con-
sidered versus the degree of benefit obtained. For example, the 
meta-analysis by Choi (2015) also noted that there were clear 
signals for treatment-emergent akathisia and nausea, along with 
one report of sinus tachycardia and two of significant worsening 
of psychotic symptoms in the aripiprazole augmentation arms.
The meta-analysis by Srisurapanont (2015) reported modest 
improvement in LDL cholesterol with aripiprazole augmentation 
but did not find any beneficial effects of the combination with 
respect to fasting plasma glucose, although it should be noted 
that the durations of the included studies were short, ranging 
from 8 to 24 weeks.
Definition of high-dose antipsychotic 
medication and recommendations in 
evidence-based clinical guidelines
A number of approaches have been used to determine whether a 
combination of antipsychotic medication is considered to be high 
dose or not (Barnes et al., 2014); the most common are (1) the use 
of ‘chlorpromazine equivalents’ where the doses of each antipsy-
chotic medication are converted to an equivalent dose of chlor-
promazine, based partially on known affinity for D2 receptors, 
and a total equivalent dose of chlorpromazine above 1000 mg is 
defined as a high dose, and; (2) the more commonly used ‘per-
centage method’ where the percentages of the maximum licensed 
dose for each antipsychotic medication co-prescribed are added 
and a cumulative dose of more than 100% is defined as a high 
dose. While both methods are essentially arbitrary and have their 
limitations, they provide a dosage threshold above which the evi-
dence suggests that the risk-benefit balance becomes more uncer-
tain and potentially unfavourable (Leucht et al., 2020) and which 
should be a prompt that such regimens should be prescribed as 
individual therapeutic trials, with close monitoring of target 
symptoms and potential side effects. Guideline recommendations 
relating to the use of high-dose or combined antipsychotic medi-
cation strategies are not based simply on whether a dosage 
threshold has been exceeded, but consider the available evidence 
relating to efficacy and safety, to inform the rational prescription 
of such regimens. Nevertheless, as the evidence base is con-
stantly developing and changing, there is a need to keep all 
guideline recommendations under review.
Conclusion
Where evidence-based medication strategies (including clozap-
ine) for schizophrenia have failed or are not tolerated, an indi-
vidual therapeutic trial of combined antipsychotic medications is 
a potential treatment option. In this context, a trial of aripiprazole 
augmentation of another antipsychotic medication may offer 
worthwhile benefits for some patients in some clinical circum-
stances. However, given the relatively poor evidence base under-
pinning the use of combined antipsychotic medications, the 
advice that other pharmacological interventions with more con-
sistent evidence for a favourable risk-benefit balance should be 
given priority and that if such a regimen is prescribed there is a 
responsibility to document the rationale for the chosen combina-
tion and carefully monitor the benefits and harms, should support 
judicious prescribing.
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Response to Paton and Barnes
Arguably the biggest concern in schizophrenia research is that of 
people with schizophrenia whose symptoms do not respond to 
standard antipsychotic agents (James Lind Alliance, 2011). Until 
more effective drugs are introduced which address this problem, it 
is important to provide a therapeutic environment that offers clini-
cians and their patients the most flexibility in treatment choice 
without restrictions that are not firmly grounded in evidence. To 
my mind, this includes the opportunity to provide a relatively safe 
treatment with a D2 partial agonist additional to a D2 antagonist, 
while recognising of course that, as with all pharmacotherapy, 
there is a balance to be struck between risk and benefit.
Paton and Barnes have prepared an extensive response to my 
commentary, starting by summarising the guidelines for the treat-
ment of schizophrenia. These recommend monotherapy and 
switching to an alternative antipsychotic agent if this is not toler-
ated or if the illness fails to respond. Only the first of these rea-
sons to switch has a strong evidence base. They also discuss at 
length the evidence for the efficacy and tolerability, or otherwise, 
of aripiprazole treatment for schizophrenia. They repeatedly 
describe benefits of adjunctive aripiprazole as modest; however, 
less than modest supporting evidence is no barrier to inclusion in 
guidelines, as we see with the recommendation to switch drugs 
for lack of response. We can recognise this as a pragmatic recom-
mendation – ‘what else can be done?’ - in the hope that some 
individual factor may result in improvement, but evidence sug-
gests it remains unlikely to be effective.
There is much opportunity for further debate around the 
effects of aripiprazole that Paton and Barnes discuss so compre-
hensively. One point they make is, however, misleading. They 
reiterate a comment in the abstract of Polcwiartek et al. (2015) 
that epidemiological studies have linked aripiprazole to weak/
moderate torsadogenicity. Yet the authors also state that a ‘lack 
of adequate data . . . confounds the interpretation of any epide-
miological findings’. More importantly, the main finding of this 
review and meta-analysis of aripiprazole’s cardiac safety in 
patients at high risk for torsade is that QTc prolongation risk is 
lower compared with both placebo and active controls. In a 
more recent population-based Danish study (Polcwiartek et al., 
2020), the same research group report that, while antipsychotic 
prescribing in people with schizophrenia was associated with a 
greater frequency of abnormal ECGs compared to non-psychi-
atric control subjects, this was not true for aripiprazole which 
was additionally associated with a decreased risk of QTc pro-
longation. It would be reasonable to conclude that aripiprazole 
is relatively safe in terms of this measure of cardiac toxicity.
One final point: while I have not specifically considered the 
adjunctive use of partial D2 agonists with clozapine, Paton and 
Barnes have helpfully drawn attention to the study of Tiihonen 
et al. (2019). The key finding from this nationwide Finnish study 
is that aripiprazole and clozapine polypharmacy is significantly 
more effective in reducing rehospitalization than clozapine or 
any antipsychotic monotherapy alone. While the effect size may 
be small, we are reminded by the authors that this may be an 
underestimate as adjunctive treatment is generally in response to 
a worsening of symptoms with monotherapy. Tiihonen et al. 
(2019) conclude that a rational polypharmacy with two particular 
drugs of differing receptor profiles appears feasible, and that 
treatment guidelines which discourage all antipsychotic polyp-
harmacy should be modified accordingly. While this has not been 
the main point of my commentary, such evidence-based polyp-
harmacy would be facilitated by the removal of a ‘high dose’ 
restriction on adjunctive D2 partial agonists that has no pharma-
cological rationale.
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